Motilal Oswal has raised target price to Rs 900 and maintained a ‘buy’ rating on the back of improving traction in specialty products. Edel...

If I adjust the numbers for Taro (a very poor number with 75% decline year on year), then overall the numbers look good to me.

Kotak Securities expects 16.4 per cent drop in profit at Rs 1,036.50 crore.

The company informed stock exchanges about the USFDA nod after market hours of Wednesday.

The drug which will be sold under the brand name Ilumya is expected to treat adults for moderate to severe plaque psoriasis, an autoimmune ...

The FDA approval of the drug was supported by data from the pivotal phase-3 resurface clinical development program, it said.